α-Interferon 2a and 13-cis-retinoic acid for the treatment of metastatic renal cell carcinoma

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Abstract

Background: It is suggested that immunotherapy may have a better role than cytotoxic chemotherapy in the treatment of metastatic renal cell carcinoma.

Aims: A phase II study of α-interferon 2a (IFN2a) and 13-cis-retinoic acid (CRA) in the treatment of metastatic renal cell carcinoma.

Methods: Twenty-two patients with no previous systemic therapy were treated with IFN2a daily at 3 million units (MU) and escalated to 6 and 9 MU if tolerated, together with CRA given orally at 1 mg/kg per day in two divided doses. Changes in quality of life were also assessed.

Results: Twenty patients were available for assessment. Three patients (14%) achieved a partial response and five patients (23%) had stable disease. No patient achieved a complete response. A durable response was observed in partial responders with median length of response of 44 weeks (range 32−59 weeks). Therapy was stopped in seven (35%) patients due to treatment-related toxicities, and quality of life was worsened in the majority of patients.

Conclusion: IFN2a and CRA has a low response rate and significant toxicity, and the combination as standard treatment of metastatic renal cell carcinoma is not recommended, despite the suggestion that CRA may lengthen the response to IFN2a. (Intern Med J 2002; 32: 158−162)

Keywords: 13-cis-retinoic acid; metastatic; renal cell carcinoma; α-interferon 2a

Document Type: Research Article

DOI: http://dx.doi.org/10.1046/j.1444-0903.2001.00184.x

Affiliations: 1: Medical Oncology, and 2: Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia 3: Urology, Westmead Hospital, Sydney and

Publication date: April 1, 2002

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more